152 related articles for article (PubMed ID: 11366351)
21. Protease inhibitors-at-a-glance.
Notes Undergr; 1996 Apr; (no 32):4-5. PubMed ID: 11363449
[TBL] [Abstract][Full Text] [Related]
22. [Resistance to protease inhibitors].
Clotet B; Martínez-Picado J; Arrizabalaga J; Ruiz L
Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):34-41. PubMed ID: 11428058
[No Abstract] [Full Text] [Related]
23. Trials for protease failure.
Posit Aware; 1998; 9(5):16-7. PubMed ID: 11365884
[TBL] [Abstract][Full Text] [Related]
24. Anti-HIV agents. Saquinavir with fosamprenavir.
TreatmentUpdate; 2004; 16(3):9. PubMed ID: 17219609
[No Abstract] [Full Text] [Related]
25. Protease inhibitor new math.
Gilden D
GMHC Treat Issues; 1996 May; 10(5):3-6. PubMed ID: 11363583
[TBL] [Abstract][Full Text] [Related]
26. [FPV plus SQV plus a mini-dose ritonavir. "Double boosting with compatible partners].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():92-3. PubMed ID: 15373070
[No Abstract] [Full Text] [Related]
27. A review of low-dose ritonavir in protease inhibitor combination therapy.
Cooper CL; van Heeswijk RP; Gallicano K; Cameron DW
Clin Infect Dis; 2003 Jun; 36(12):1585-92. PubMed ID: 12802760
[TBL] [Abstract][Full Text] [Related]
28. [Clinical application of HIV protease inhibitors].
Chiba N; Shintani M; Ueno T; Hayashi H
Tanpakushitsu Kakusan Koso; 1998 May; 43(6):744-51. PubMed ID: 9612068
[No Abstract] [Full Text] [Related]
29. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
Kuschak D; Mauss S; Schmutz G; Gantke B
Clin Lab; 2001; 47(9-10):471-7. PubMed ID: 11596909
[TBL] [Abstract][Full Text] [Related]
30. Conference looks at HIV drug resistance.
Chang HE
GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910
[TBL] [Abstract][Full Text] [Related]
31. Protease inhibitors at a glance...
Notes Undergr; 1998-1999 Winter; (No 38):suppl 1-4. PubMed ID: 11366198
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite.
Verbesselt R; Van Wijngaerden E; de Hoon J
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jan; 845(1):51-60. PubMed ID: 16997640
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference.
Prescott LM
Body Posit; 1998 Dec; 11(12):11-2. PubMed ID: 11366134
[TBL] [Abstract][Full Text] [Related]
34. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
35. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
36. Kaletra versus nelfinavir.
TreatmentUpdate; 2001; 12(12):8-10. PubMed ID: 11570097
[No Abstract] [Full Text] [Related]
37. Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.
Blanco JL; Biglia MA; Arnedo M; Martínez E; Mallolas J; Milinkovic A; Laguno M; Larrousse M; Leon A; Lonca M; García F; Miró JM; Pumarola T; Gatell JM
AIDS; 2005 May; 19(8):829-31. PubMed ID: 15867498
[TBL] [Abstract][Full Text] [Related]
38. Anti-HIV agents. A protease-only regimen--Kaletra and saquinavir.
TreatmentUpdate; 2004; 16(3):8. PubMed ID: 17216837
[No Abstract] [Full Text] [Related]
39. Two possible pathways for acquisition of mutations related to nelfinavir resistance.
Sugiura W; Oishi T; Okano A; Matsuda M; Abumi H; Yamada K; Koike M; Taki M; Ishikawa M; Miura T; Fukutake K; Gouchi K; Ajisawa A; Iwamoto A; Hanabusa H; Mimaya J; Takamatsu J; Takata N; Kakishita E; Higasa S; Kashiwagi S; Shirahata A; Nagai Y
Jpn J Infect Dis; 1999 Aug; 52(4):175-6. PubMed ID: 10592904
[No Abstract] [Full Text] [Related]
40. Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
Jayakanthan M; Chandrasekar S; Muthukumaran J; Mathur PP
J Mol Graph Model; 2010 Jan; 28(5):455-63. PubMed ID: 19931478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
